A new market research report on the Global Engineered T Cells market has introduced by KD Market Insights. The report is dedicated to in-depth industry analysis of the global Engineered T Cells market. The Global Engineered T Cells Market analysis is broken down on different segmentation levels including Market By Type, By Application, By End User.
T cell is a type of white blood cell, and plays an important role in cell-medicated immunity. Engineered T cells are genetically modified T cells, specifically altered for therapeutic actions against autoimmune diseases and various types of cancers. The engineered T cells are delivered into patient's body to reduce toxicity levels and restrict antigen escape (inability of immune system to respond to an infectious agent) for elimination of cancerous cells. The global engineered T cells market was valued at $145.97 million in 2016, and is estimated to reach at $2,124.02 million by 2023, registering a CAGR of 46.5% from 2017 to 2023.
Get Report Sample Copy @ https://www.kdmarketinsights.com/sample/3520
Increase in of incidence of various types of cancers and autoimmune diseases is projected to drive the growth of the engineered T cells market. In addition, advantages offered by engineered T cells therapies over traditional cancer treatments such as chemotherapy, high technological advancements, and increase access to medical insurance are expected to boost the market growth. However, high cost associated with T cells therapies and lack of awareness about T cells therapies hinder the growth of this market.
The engineered T cells market is segmented based on type, application, end user, and geography. On the basis of type, the market is categorized into chimeric antigen receptor (CAR) modified T cells, tumor infiltrating lymphocytes (TIL), and T cells receptor (TCR) modified T cells. By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia, and other applications. Depending on end user, it is fragmented into hospitals, cancer research centers, and clinics. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global engineered T-cells market and the current trends and future estimations to elucidate the imminent investment pockets.
- It presents a quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market based on end user assists to understand the trends in the industry.
- Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Type
- Chimeric Antigen Receptor (CAR)
- Tumor Infiltrating Lymphocytes (TIL)
- T-cell Receptor (TCR)
By Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Leukemia
- Others
By End User
- Hospitals
- Cancer Research Centers
- Clinics
By Region
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Taiwan
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY PLAYERS PROFILED IN THE REPORT
- Autolus Limited
- Bellicum Pharmaceuticals, Inc.
- Cell Medica
- Elli Lilly and Company
- Gilead Sciences, Inc.
- Juno Therapeutics
- Novartis AG
- Oxford Biomedica
- vPfizer Inc.
- Precision Bioscience
Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/engineered-t-cells-market-amr
Table of Content
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.2.2.1. TOP WINNING STRATEGIES, BY YEAR, 2015-2017
3.2.2.2. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2017 (%)
3.2.2.3. TOP WINNING STRATEGIES, BY COMPANY, 2015-2017
3.3. PORTERS FIVE FORCES ANALYSIS
3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry
3.4. TOP PLAYER POSITIONING, 2016
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.1.1. Increase in government expenditure for the healthcare sector
3.5.1.2. Increased access to medical insurance
3.5.1.3. Increase in geriatric population
3.5.1.4. Increase in prevalence of cancer diseases
3.5.2. Restraint
3.5.2.1. Risk of allergic reaction and limitations of the engineered T cells treatment
3.5.2.2. Stringent government regulations
3.5.2.3. High cost of engineered T cells treatment
3.5.3. Opportunity
3.5.3.1. Increase in R&D in engineered T cells
3.5.3.2. Lucrative opportunities from emerging economies
CHAPTER 4 ENGINEERED T CELLS MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED T CELLS
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.3. T CELLS RECEPTOR (TCR) MODIFIED T CELLS
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.4. TUMOR INFILTRATING LYMPHOCYTES
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
CHAPTER 5 ENGINEERED T CELLS MARKET, BY APPLICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. LUNG CANCER
5.2.1. Market size and forecast
5.3. BREAST CANCER
5.3.1. Market size and forecast
5.4. COLORECTAL CANCER
5.4.1. Market size and forecast
5.5. MELANOMA
5.5.1. Market size and forecast
5.6. LEUKEMIA
5.6.1. Market size and forecast
5.7. OTHERS APPLICATIONS
5.7.1. Market size and forecast
CHAPTER 6 ENGINEERED T CELLS MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HOSPITALS
6.2.1. Market size and forecast
6.3. CANCER RESEARCH CENTERS
6.3.1. Market size and forecast
6.4. CLINICS
6.4.1. Market size and forecast
CHAPTER 7 ENGINEERED T CELLS MARKET, BY REGION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast
7.2.3. U.S. market size and forecast
7.2.4. Canada market size and forecast
7.2.5. Mexico market size and forecast
7.3. EUROPE
7.3.1. Key market trends and opportunities
7.3.2. Market size and forecast
7.3.3. Germany market size and forecast
7.3.4. France market size and forecast
7.3.5. UK market size and forecast
7.3.6. Italy market size and forecast
7.3.7. Spain market size and forecast
7.3.8. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
7.4.1. Key market trends and opportunities
7.4.2. Market size and forecast
7.4.3. Japan market size and forecast
7.4.4. China market size and forecast
7.4.5. India market size and forecast
7.4.6. Australia market size and forecast
7.4.7. South Korea market size and forecast
7.4.8. Taiwan market size and forecast
7.4.9. Rest of Asia-Pacific market size and forecast
Continue @...
Check for Discount @ https://www.kdmarketinsights.com/discount/3520
About Us:
KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: http://www.kdmarketinsights.com
Read More:
https://pr-wire.blogspot.com/
https://dailyprpost.blogspot.com/
T cell is a type of white blood cell, and plays an important role in cell-medicated immunity. Engineered T cells are genetically modified T cells, specifically altered for therapeutic actions against autoimmune diseases and various types of cancers. The engineered T cells are delivered into patient's body to reduce toxicity levels and restrict antigen escape (inability of immune system to respond to an infectious agent) for elimination of cancerous cells. The global engineered T cells market was valued at $145.97 million in 2016, and is estimated to reach at $2,124.02 million by 2023, registering a CAGR of 46.5% from 2017 to 2023.
Get Report Sample Copy @ https://www.kdmarketinsights.com/sample/3520
Increase in of incidence of various types of cancers and autoimmune diseases is projected to drive the growth of the engineered T cells market. In addition, advantages offered by engineered T cells therapies over traditional cancer treatments such as chemotherapy, high technological advancements, and increase access to medical insurance are expected to boost the market growth. However, high cost associated with T cells therapies and lack of awareness about T cells therapies hinder the growth of this market.
The engineered T cells market is segmented based on type, application, end user, and geography. On the basis of type, the market is categorized into chimeric antigen receptor (CAR) modified T cells, tumor infiltrating lymphocytes (TIL), and T cells receptor (TCR) modified T cells. By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia, and other applications. Depending on end user, it is fragmented into hospitals, cancer research centers, and clinics. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global engineered T-cells market and the current trends and future estimations to elucidate the imminent investment pockets.
- It presents a quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market based on end user assists to understand the trends in the industry.
- Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Type
- Chimeric Antigen Receptor (CAR)
- Tumor Infiltrating Lymphocytes (TIL)
- T-cell Receptor (TCR)
By Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Leukemia
- Others
By End User
- Hospitals
- Cancer Research Centers
- Clinics
By Region
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Taiwan
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY PLAYERS PROFILED IN THE REPORT
- Autolus Limited
- Bellicum Pharmaceuticals, Inc.
- Cell Medica
- Elli Lilly and Company
- Gilead Sciences, Inc.
- Juno Therapeutics
- Novartis AG
- Oxford Biomedica
- vPfizer Inc.
- Precision Bioscience
Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/engineered-t-cells-market-amr
Table of Content
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.2.2.1. TOP WINNING STRATEGIES, BY YEAR, 2015-2017
3.2.2.2. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2017 (%)
3.2.2.3. TOP WINNING STRATEGIES, BY COMPANY, 2015-2017
3.3. PORTERS FIVE FORCES ANALYSIS
3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry
3.4. TOP PLAYER POSITIONING, 2016
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.1.1. Increase in government expenditure for the healthcare sector
3.5.1.2. Increased access to medical insurance
3.5.1.3. Increase in geriatric population
3.5.1.4. Increase in prevalence of cancer diseases
3.5.2. Restraint
3.5.2.1. Risk of allergic reaction and limitations of the engineered T cells treatment
3.5.2.2. Stringent government regulations
3.5.2.3. High cost of engineered T cells treatment
3.5.3. Opportunity
3.5.3.1. Increase in R&D in engineered T cells
3.5.3.2. Lucrative opportunities from emerging economies
CHAPTER 4 ENGINEERED T CELLS MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED T CELLS
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.3. T CELLS RECEPTOR (TCR) MODIFIED T CELLS
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.4. TUMOR INFILTRATING LYMPHOCYTES
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
CHAPTER 5 ENGINEERED T CELLS MARKET, BY APPLICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. LUNG CANCER
5.2.1. Market size and forecast
5.3. BREAST CANCER
5.3.1. Market size and forecast
5.4. COLORECTAL CANCER
5.4.1. Market size and forecast
5.5. MELANOMA
5.5.1. Market size and forecast
5.6. LEUKEMIA
5.6.1. Market size and forecast
5.7. OTHERS APPLICATIONS
5.7.1. Market size and forecast
CHAPTER 6 ENGINEERED T CELLS MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HOSPITALS
6.2.1. Market size and forecast
6.3. CANCER RESEARCH CENTERS
6.3.1. Market size and forecast
6.4. CLINICS
6.4.1. Market size and forecast
CHAPTER 7 ENGINEERED T CELLS MARKET, BY REGION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast
7.2.3. U.S. market size and forecast
7.2.4. Canada market size and forecast
7.2.5. Mexico market size and forecast
7.3. EUROPE
7.3.1. Key market trends and opportunities
7.3.2. Market size and forecast
7.3.3. Germany market size and forecast
7.3.4. France market size and forecast
7.3.5. UK market size and forecast
7.3.6. Italy market size and forecast
7.3.7. Spain market size and forecast
7.3.8. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
7.4.1. Key market trends and opportunities
7.4.2. Market size and forecast
7.4.3. Japan market size and forecast
7.4.4. China market size and forecast
7.4.5. India market size and forecast
7.4.6. Australia market size and forecast
7.4.7. South Korea market size and forecast
7.4.8. Taiwan market size and forecast
7.4.9. Rest of Asia-Pacific market size and forecast
Continue @...
Check for Discount @ https://www.kdmarketinsights.com/discount/3520
About Us:
KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: http://www.kdmarketinsights.com
Read More:
https://pr-wire.blogspot.com/
https://dailyprpost.blogspot.com/
No comments:
Post a Comment